On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug Administration for Xpertﾮ Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.

The four-in-one test was designed for use on any of Cepheid’s over 26,000 GeneXpertﾮ Systems placed worldwide, with results delivered in approximately 36 minutes.